CollPlant Biotechnologies Files 6-K Report
Ticker: CLGN · Form: 6-K · Filed: Aug 20, 2025 · CIK: 1631487
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, regulatory-update
TL;DR
CollPlant filed a 6-K, standard foreign issuer report for Q2 2025.
AI Summary
CollPlant Biotechnologies Ltd. filed a Form 6-K on August 20, 2025, reporting for the period ending June 30, 2025. The company, incorporated in Israel, operates in the orthopedic, prosthetic, and surgical appliances sector. This filing is a routine report for foreign private issuers.
Why It Matters
This filing provides an update on CollPlant's regulatory reporting status as a foreign private issuer, which is important for investors tracking their compliance and disclosures.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer information and does not contain new financial results or significant operational updates.
Key Numbers
- 001-38370 — SEC File Number (Identifies the company's registration with the SEC.)
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- August 20, 2025 (date) — Filing Date
- June 30, 2025 (date) — Reporting Period End Date
- Israel (location) — Country of Incorporation
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
What is the reporting period for this specific 6-K filing?
The conformed period of report for this filing is June 30, 2025.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on August 20, 2025.
What industry does CollPlant Biotechnologies Ltd. operate in?
CollPlant Biotechnologies Ltd. operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, SIC code 3842.
Does CollPlant Biotechnologies Ltd. file annual reports under Form 20-F or 40-F?
CollPlant Biotechnologies Ltd. indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 416 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2025-08-20 08:00:59
Filing Documents
- ea0253655-6k_collplant.htm (6-K) — 18KB
- ea025365501ex99-1_collplant.htm (EX-99.1) — 128KB
- ea025365501ex99-2_collplant.htm (EX-99.2) — 354KB
- ea025365501ex99-3_collplant.htm (EX-99.3) — 89KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-25-078731.txt ( ) — 3212KB
- clgn-20250630.xsd (EX-101.SCH) — 29KB
- clgn-20250630_cal.xml (EX-101.CAL) — 25KB
- clgn-20250630_def.xml (EX-101.DEF) — 143KB
- clgn-20250630_lab.xml (EX-101.LAB) — 290KB
- clgn-20250630_pre.xml (EX-101.PRE) — 161KB
- ea0253655-6k_collplant_htm.xml (XML) — 299KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: August 20, 2025 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 3